Quick Answer
India’s pharmaceutical patent framework, anchored by Section 3(d) of the Patents Act, 1970, prohibits evergreening and sets an enhanced therapeutic efficacy standard for patent grants. Confirmed constitutional by the Supreme Court in Novartis AG v. Union of India (2013), Section 3(d) shapes every strategic decision for pharma innovators and generics operating in India.
India’s pharmaceutical patent framework remains the most scrutinized and debated in the world. Section 3(d) of the Patents Act, 1970 has made India a model for developing nations seeking to balance pharmaceutical innovation with access to medicines. The Supreme Court’s landmark ruling in Novartis AG v. Union of India (2013) confirmed its constitutional validity and established the enhanced therapeutic efficacy standard as a fixed gatekeeping requirement.
Compulsory licensing has been granted once, in Natco Pharma v. Bayer Corporation (2012), reducing the monthly price of Nexavar from approximately ₹2.84 lakh to ₹8,880, with a 3% royalty payable to Bayer. This case has not been replicated since, but its precedent governs risk assessment across the industry.
For IP and regulatory heads at innovator companies, biotech founders, and patent attorneys advising pharma clients, understanding India’s patent strategy is not optional. It is existential.
Why India's Patent Law Treats Pharma Differently
India’s Patents Act, 1970, as amended in 2005, incorporates public health safeguards that are unique among major economies. Three structural features define the landscape:
- Section 3(d): Prevents patent evergreening by requiring that new forms of known substances demonstrate significantly enhanced therapeutic efficacy.
- Section 84: Enables compulsory licensing for public health purposes after three years from patent grant, on any of three statutory grounds.
- Absence of data exclusivity and patent linkage: Clinical trial data submitted to the Central Drugs Standard Control Organisation (CDSCO) can be referenced immediately by generic applicants. The CDSCO does not link drug approval to patent status.
These provisions collectively define pharmaceutical patent strategy in India in a way that differs materially from the United States, European Union, and most other jurisdictions.
Section 3(d): The Evergreening Barrier
What Section 3(d) Says
Section 3(d) of the Patents Act, 1970 excludes from patentability “the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance.” It covers salts, esters, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations, and derivatives.
The phrase “enhancement of the known efficacy” carries the operative weight. For pharmaceutical substances, the Indian Patent Office applies a strict interpretation: bioavailability improvements alone are insufficient. The applicant must demonstrate enhanced therapeutic efficacy through comparative clinical or pharmacological data.
The Novartis/Gleevec Ruling: Supreme Court 2013
The Supreme Court’s decision in Novartis AG v. Union of India (2013) is the most consequential judicial ruling on pharmaceutical patents in Indian legal history. Novartis sought a patent for the beta crystalline form of imatinib mesylate (Gleevec/Glivec), claiming improved bioavailability over imatinib freebase.
The Supreme Court upheld the rejection on three grounds:
- Imatinib mesylate was anticipated by the Zimmermann patent (granted 1993) and was therefore a known substance.
- The beta crystalline form represented a new physical form of a known substance, precisely within Section 3(d)’s exclusion.
- Improved bioavailability did not constitute enhanced therapeutic efficacy for the purpose of Section 3(d).
The ruling confirmed the constitutional validity of Section 3(d), rejected the argument that it violated the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and established that TRIPS flexibilities permit member states to define patentability criteria. This ruling continues to govern every Section 3(d) analysis conducted before the Indian Patent Office. For a broader overview of how Indian patent law applies to the life sciences sector, see our related guide on pharmaceutical patents and IP strategy in India.
How to Navigate Section 3(d): Practical Strategy
For innovators seeking patent protection on new forms or derivatives of known pharmaceutical substances, we recommend the following approach:
- Generate comparative therapeutic efficacy data early. Clinical or pre-clinical data demonstrating superiority over the parent compound, not merely improved solubility or bioavailability, is the foundational requirement.
- Draft claims around novel molecular entities where possible. First-in-class NCEs are not subject to Section 3(d)’s bar and should receive prosecution priority.
- Anticipate pre-grant oppositions. Any person may file a pre-grant opposition under Section 25(1) of the Patents Act, 1970. Third parties, including generic manufacturers, routinely deploy this mechanism against pharmaceutical applications.
- Build a prosecution record that addresses efficacy explicitly. Examiners and opposition boards will scrutinize the specification. Weak efficacy arguments create vulnerability in both prosecution and subsequent post-grant opposition proceedings.
Patent Filing Strategy for Pharma Companies in India
Filing Timeline: Before Any Disclosure
India does not provide a statutory grace period for pre-filing disclosures in most circumstances. A public disclosure prior to filing destroys novelty. Patent applications must be filed before any regulatory submission, publication, conference presentation, or commercial activity that constitutes prior art.
For international protection, we advise filing an international application under the Patent Cooperation Treaty (PCT) to secure priority and defer national phase entry costs while maintaining flexibility across jurisdictions. Our post on PCT filing strategy covers this process in detail.
Which Claims to File in India
India permits product and process claims for pharmaceutical patents. However, the practical scope of protection is shaped by Section 3(d) and Section 3(e) (which bars patents on admixtures). Key claim categories to prioritize include:
- Novel chemical entities and novel biological entities
- Specific crystalline forms with demonstrated enhanced efficacy
- New treatment indications where the compound itself is patentable
- Manufacturing process claims with genuine inventive distinction from prior art
Formulation patents, combination patents, and dosage regimen patents face elevated scrutiny and should be supported by robust inventive step arguments beyond the Section 3(d) efficacy requirement.
Divisional and Continuation Applications
The Patents Act, 1970 permits divisional applications under Section 16 where a single application contains more than one invention. Strategic use of divisional filings extends the prosecution timeline and allows applicants to respond to objections while preserving claim scope on related subject matter. This is particularly relevant for pharma applicants managing large compound portfolios.
Compulsory Licensing: Assessing the Risk
Section 84: Grounds for Compulsory Licensing
Section 84 of the Patents Act, 1970 permits any person to apply for a compulsory licence (CL) after three years from the date of patent grant on any of three grounds:
- The reasonable requirements of the public with respect to the patented invention have not been satisfied.
- The patented invention is not available to the public at a reasonably affordable price.
- The patented invention is not worked in the territory of India.
All three grounds are independent. An applicant need only establish one to qualify for consideration by the Controller of Patents.
Natco/Bayer: Nexavar (2012): The Only Granted Compulsory Licence
In Natco Pharma Ltd. v. Bayer Corporation (2012), the Controller of Patents granted India’s first and, to date, only compulsory licence for the drug sorafenib tosylate (Nexavar), used in the treatment of kidney and liver cancer.
The Controller found that Bayer had failed on all three Section 84 grounds. The drug was not available to most patients requiring it, the price (approximately ₹2.84 lakh per month) was not reasonably affordable, and Bayer had not worked the patent in India through domestic manufacturing. The compulsory licence was granted to Natco Pharma at a royalty of 3% of net sales, with the price fixed at ₹8,880 per month.
The Intellectual Property Appellate Board and subsequently the Bombay High Court upheld the grant. This decision remains the operative precedent for compulsory licensing risk analysis in India.
How to Minimise Compulsory Licensing Risk
Based on the Natco/Bayer precedent and the statutory framework, we advise the following measures:
- Establish domestic working. Section 83 of the Patents Act, 1970 sets out the principles governing patent working. Local manufacture or substantive domestic supply through licensing satisfies the working requirement more reliably than imports alone.
- Maintain patient access programmes. Structured programmes that make patented medicines available at tiered pricing reduce the “reasonably affordable price” vulnerability.
- File annual Form 27 statements accurately and on time. Working statements are due by 31 March each year for the preceding calendar year. Failure to file, or filing inaccurate statements, constitutes grounds for both compulsory licensing applications and penalty proceedings.
- Monitor Section 92 government use provisions. In circumstances of national emergency or public non-commercial use, the Government of India may invoke Section 92 to grant CLs without the standard three-year waiting period.
Biosimilar and Biologics Patent Strategy in India
India’s regulatory framework for similar biologics is governed by the Guidelines on Similar Biologics issued by CDSCO in 2012, developed jointly with the Department of Biotechnology. These guidelines establish a comparability exercise pathway for biosimilar applicants but do not create data exclusivity or any patent linkage mechanism.
For innovator biologics companies, this creates a strategic gap. Unlike small molecule drugs, biologic patents often cover production processes, cell lines, and formulations rather than the molecule itself, since many biologics are naturally derived proteins. This makes claim architecture more complex and prosecution strategy more consequential.
Key actions for biologics patent strategy in India include:
- File layered patent families covering the molecule, production process, formulation, and any novel delivery mechanism as separate applications.
- Pursue patent term adjustments and extensions where applicable, recognising that India does not currently provide formal patent term extension for regulatory delays, unlike the United States Hatch-Waxman framework.
- Monitor biosimilar applicant disclosures through CDSCO filings and coordinate with regulatory counsel to evaluate whether biosimilar clinical data packages infringe process or formulation claims.
- Align PCT filing strategy with jurisdictions that do offer data exclusivity (European Union, United States) to create complementary multi-jurisdictional protection portfolios.
Patent Working Requirements: Mandatory Statements
Section 146 of the Patents Act, 1970, read with Rule 131 of the Patents Rules, 2003, requires every patentee and licensee to file Form 27 annually. The statement must disclose the extent to which the patented invention has been worked commercially in India during the preceding year.
Key compliance points:
- Filing deadline: 31 March each year, covering the preceding calendar year.
- Scope: Required from both patentees and exclusive licensees.
- Content: Commercial working status, approximate value of the working, and whether public requirements have been met.
- Consequences of non-compliance: Section 122 provides for penalties. Non-working is a direct ground for compulsory licensing applications under Section 84.
Form 27 data is publicly accessible. Generic manufacturers and third-party challengers routinely review these filings to identify compulsory licensing opportunities. Accurate, complete, and strategically informed Form 27 filings are a core element of pharmaceutical patent portfolio management.
Altacit Global: Your Pharmaceutical IP Partner
Altacit Global’s IP practice advises pharmaceutical and biotech companies on the full spectrum of patent prosecution, Section 3(d) strategy, compulsory licensing defence, biologics patent architecture, and Form 27 compliance. Our teams, based in Hyderabad and Chennai, combine technical pharmaceutical expertise with deep knowledge of Indian patent law and CDSCO regulatory requirements.
Pharma companies at any stage of market entry or portfolio development benefit from structuring their India IP strategy early. The decisions made at filing, during prosecution, and through the working statement cycle define the defensibility of an entire product position.
Contact Altacit Global at info@altacit.com to discuss your pharmaceutical patent strategy in India.
Frequently Asked Questions: Pharmaceutical Patents India
Q1: Can a new salt or polymorph of a known drug be patented in India?
A new salt or polymorph of a known pharmaceutical compound can only be patented in India if the applicant demonstrates significantly enhanced therapeutic efficacy compared to the known substance, as required under Section 3(d) of the Patents Act, 1970. Improved solubility or bioavailability, without corresponding therapeutic superiority, does not satisfy this standard under the Novartis/Gleevec Supreme Court ruling of 2013.
Q2: How does India's compulsory licensing regime compare to TRIPS flexibilities?
India’s compulsory licensing provisions under Sections 84, 92, and 92A of the Patents Act, 1970 directly implement the flexibilities recognised in Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights and the 2001 Doha Declaration on TRIPS and Public Health. India’s approach is notable for its three independent statutory grounds under Section 84, its explicit working requirements, and its absence of data exclusivity, each of which collectively produce a more favourable environment for generic market entry than most TRIPS-compliant jurisdictions.
Q3: What does "working a patent" mean in India under Section 146?
Working a patent in India means the commercial exploitation of the patented invention within Indian territory, whether through manufacture, sale, or licensing. Patentees must file Form 27 annually by 31 March, disclosing the extent of commercial working. Importation without domestic manufacture or production is generally considered insufficient working, and non-working remains one of the three independent grounds for a compulsory licensing application under Section 84 of the Patents Act, 1970.
Q4: Can a foreign pharmaceutical company challenge an Indian patent?
Yes. Any person, including a foreign pharmaceutical company, may file a pre-grant opposition under Section 25(1) of the Patents Act, 1970 before patent grant, or a post-grant opposition under Section 25(2) within twelve months of publication of the patent grant. Additionally, any interested person may file a revocation petition before the Intellectual Property Division of the relevant High Court under Section 64. Foreign companies and their Indian subsidiaries routinely use these mechanisms to challenge competitor pharmaceutical patents in India.
Q5: Is India's biosimilar approval pathway linked to the innovator's patent status?
No. India does not operate a patent linkage system. The CDSCO does not review or consider patent status when evaluating a Similar Biologics application under the Guidelines on Similar Biologics, 2012. A biosimilar may receive marketing approval regardless of whether the innovator’s patents remain in force. This places the burden on innovator companies to enforce their patents independently through civil patent infringement proceedings before the appropriate High Court.
